E-13 | Percutaneous Coronary Interventions of Balloon Uncrossable Chronic Total Occlusions
Notice bibliographique
Résumé
BackgroundBalloon uncrossable lesions are defined as lesions that cannot be crossed with a balloon after successful guidewire crossing.MethodsWe analyzed the association between balloon uncrossable lesions (BU) and procedural outcomes of 6,883 chronic total occlusion (CTO) percutaneous coronary intervention (PCI)s performed between 2012 and 2021 at 36 centers.ResultsThe prevalence of balloon uncrossable lesions was 9.5%. Mean patient age was 64.2±10 years and 81% were men. Patients with balloon uncrossable lesions were older (67.4 ± 10 vs. 63.9 ± 10, p<0.001), more likely to have diabetes mellitus (50% vs. 42%, p<0.001) and prior coronary artery bypass graft surgery (40% vs. 26%, p<0.001) compared with patients who had balloon crossable lesions. Calcification (68% vs. 40%, p<0.001) and proximal vessel tortuosity (37% vs. 25%, p<0.001) were more common in balloon uncrossable lesions. Procedure time (133 [87, 199] vs. 111 [72, 165] min, p<0.001) was longer and air kerma radiation dose (2.60 [1.49, 4.20] vs. 1.98 [1.10, 3.40] min, p<0.001) was higher in balloon uncrossable lesions, and they also had lower technical (90% vs. 98%, p<0.001) and procedural success rates (87% vs. 97%, p<0.001) and higher major adverse complication event rates (3.21% vs. 1.46%, p<0.001). The techniques used for balloon uncrossable lesions and the associated technical success rates are shown in Figure 1.ConclusionsDisclosuresK. Alaswad: consultant and speaker for Boston Scientific, Abbott Cardiovascular, Teleflex, and CSI: Consulting; J. Khatri: Medtronic, Abbott, Boston, Terumo, Asahi speaker/proctor.: Consulting; F. A. Jaffer: sponsored research support from Kowa, Canon, Siemens, Teleflex, Shockwave, and Amarin; consultant for Boston Scientific, Abbott Vascular, Siemens, Magenta Medical, Asahi Intecc and IMDS; has an equity interest in Intravascular Imaging, Inc. and DurVena, I: Consulting; M. P. Patel: Abbott: Consulting; Cardiovascular Systems, Inc.: Consulting; Medtronic: Consulting; A. Elguindy: Honoraria: Medtronic, Boston Scientific, Asahi Intecc, Abbott Proctorship fees: Medtronic, Boston Scientific, Asahi Intecc, Terumo Educational grants: Medtronic: Consulting; B. Jefferson: honoraria/consulting/speaking fees from Abbott, Boston Scientific, CSI, Medtronic: Consulting; J. R. Wollmuth: reports serving as proctor/speaker/medical advisory board for Abbott Vascular, Boston Scientific and Abiomed, proctor for Asahi Intecc, and medical advisory board with Philips: Advisory Board/Board Member; D. Karmpaliotis: Abbott: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; Saranas: Ownership Interests: Stocks, Stock Options; Soundbite: Ownership Interests: Stocks, Stock Options; Traverse Vascular: Ownership Interests: Stocks, Stock Options; Z. A. Ali: Abbott: Advisory Board/Board Member; Boston Scientific Corp.: Consulting and Speaker Bureau; Cardiovascular Systems, Inc.: Principal Investigator for a Research Study; Amgen: Advisory Board/Board Member; Astra Zeneca: Speaker Bureau; Shockwave Medical: Ownership Interests: Stocks, Stock Options; R. E. Davies: Medtronic: Speaker Bureau; Asahi Intec: Speaker Bureau; Shockwave: Advisory Board/Board Member; Siemens healthineers/Corindus: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; D. Doshi: speaker’s bureau for Abbott Vascular, Boston Scientific, and Medtronic and has research support from Biotronik: Consulting; M. B. Basir: consultant for Abbott Vascular, Abiomed, Cardiovascular Systems, Chiesi, and Zoll.: Consulting; E. S. Brilakis: Abbott: Consulting and Speaker Bureau; AMgen: Consulting and Speaker Bureau; Asahi Intecc: Speaker Bureau; Biotronik: Consulting and Speaker Bureau; Boston Scientific Corp.: Consulting, Principal Investigator for a Research Study and Speaker Bureau; ControlRad: Speaker Bureau; CSI: Consulting and Speaker Bureau; GE Healthcare: Consulting, Principal Investigator for a Research Study and Speaker Bureau; Hippocrates LLC: Ownership Interests: Stocks, Stock Options; MHI Ventures: Ownership Interests: Stocks, Stock Options; Cleerly Health: Ownership Interests: Stocks, Stock Options; Stallion Medical: Ownership Interests: Stocks, Stock Options; J. Karacsonyi Nothing to disclose. O. Krestyaninov Nothing to disclose. D. Khelimskii Nothing to disclose. P. Poomipanit Nothing to disclose. J. W. Choi Nothing to disclose. Ş. Görgülü Nothing to disclose. M. Koutouzis Nothing to disclose. I. Tsiafoutis Nothing to disclose. A. M. Sheikh Nothing to disclose. B. Elbarouni Nothing to disclose. T. Patel Nothing to disclose. R. W. Yeh Nothing to disclose. A. J. Kirtane Nothing to disclose. M. McEntegart Nothing to disclose. A. Masoumi Nothing to disclose. S. Kostantinis Nothing to disclose. B. Simsek Nothing to disclose. B. V. Rangan Nothing to disclose. O. C. Mastrodemos Nothing to disclose. Y. B. Sandoval Nothing to disclose. M. S. Megaly Nothing to disclose. I. Ungi Nothing to disclose. N. Abi Rafeh Nothing to disclose. Ö. Göktekin Nothing to disclose. BackgroundBalloon uncrossable lesions are defined as lesions that cannot be crossed with a balloon after successful guidewire crossing. Balloon uncrossable lesions are defined as lesions that cannot be crossed with a balloon after successful guidewire crossing. MethodsWe analyzed the association between balloon uncrossable lesions (BU) and procedural outcomes of 6,883 chronic total occlusion (CTO) percutaneous coronary intervention (PCI)s performed between 2012 and 2021 at 36 centers. We analyzed the association between balloon uncrossable lesions (BU) and procedural outcomes of 6,883 chronic total occlusion (CTO) percutaneous coronary intervention (PCI)s performed between 2012 and 2021 at 36 centers. ResultsThe prevalence of balloon uncrossable lesions was 9.5%. Mean patient age was 64.2±10 years and 81% were men. Patients with balloon uncrossable lesions were older (67.4 ± 10 vs. 63.9 ± 10, p<0.001), more likely to have diabetes mellitus (50% vs. 42%, p<0.001) and prior coronary artery bypass graft surgery (40% vs. 26%, p<0.001) compared with patients who had balloon crossable lesions. Calcification (68% vs. 40%, p<0.001) and proximal vessel tortuosity (37% vs. 25%, p<0.001) were more common in balloon uncrossable lesions. Procedure time (133 [87, 199] vs. 111 [72, 165] min, p<0.001) was longer and air kerma radiation dose (2.60 [1.49, 4.20] vs. 1.98 [1.10, 3.40] min, p<0.001) was higher in balloon uncrossable lesions, and they also had lower technical (90% vs. 98%, p<0.001) and procedural success rates (87% vs. 97%, p<0.001) and higher major adverse complication event rates (3.21% vs. 1.46%, p<0.001). The techniques used for balloon uncrossable lesions and the associated technical success rates are shown in Figure 1. The prevalence of balloon uncrossable lesions was 9.5%. Mean patient age was 64.2±10 years and 81% were men. Patients with balloon uncrossable lesions were older (67.4 ± 10 vs. 63.9 ± 10, p<0.001), more likely to have diabetes mellitus (50% vs. 42%, p<0.001) and prior coronary artery bypass graft surgery (40% vs. 26%, p<0.001) compared with patients who had balloon crossable lesions. Calcification (68% vs. 40%, p<0.001) and proximal vessel tortuosity (37% vs. 25%, p<0.001) were more common in balloon uncrossable lesions. Procedure time (133 [87, 199] vs. 111 [72, 165] min, p<0.001) was longer and air kerma radiation dose (2.60 [1.49, 4.20] vs. 1.98 [1.10, 3.40] min, p<0.001) was higher in balloon uncrossable lesions, and they also had lower technical (90% vs. 98%, p<0.001) and procedural success rates (87% vs. 97%, p<0.001) and higher major adverse complication event rates (3.21% vs. 1.46%, p<0.001). The techniques used for balloon uncrossable lesions and the associated technical success rates are shown in Figure 1. Conclusions DisclosuresK. Alaswad: consultant and speaker for Boston Scientific, Abbott Cardiovascular, Teleflex, and CSI: Consulting; J. Khatri: Medtronic, Abbott, Boston, Terumo, Asahi speaker/proctor.: Consulting; F. A. Jaffer: sponsored research support from Kowa, Canon, Siemens, Teleflex, Shockwave, and Amarin; consultant for Boston Scientific, Abbott Vascular, Siemens, Magenta Medical, Asahi Intecc and IMDS; has an equity interest in Intravascular Imaging, Inc. and DurVena, I: Consulting; M. P. Patel: Abbott: Consulting; Cardiovascular Systems, Inc.: Consulting; Medtronic: Consulting; A. Elguindy: Honoraria: Medtronic, Boston Scientific, Asahi Intecc, Abbott Proctorship fees: Medtronic, Boston Scientific, Asahi Intecc, Terumo Educational grants: Medtronic: Consulting; B. Jefferson: honoraria/consulting/speaking fees from Abbott, Boston Scientific, CSI, Medtronic: Consulting; J. R. Wollmuth: reports serving as proctor/speaker/medical advisory board for Abbott Vascular, Boston Scientific and Abiomed, proctor for Asahi Intecc, and medical advisory board with Philips: Advisory Board/Board Member; D. Karmpaliotis: Abbott: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; Saranas: Ownership Interests: Stocks, Stock Options; Soundbite: Ownership Interests: Stocks, Stock Options; Traverse Vascular: Ownership Interests: Stocks, Stock Options; Z. A. Ali: Abbott: Advisory Board/Board Member; Boston Scientific Corp.: Consulting and Speaker Bureau; Cardiovascular Systems, Inc.: Principal Investigator for a Research Study; Amgen: Advisory Board/Board Member; Astra Zeneca: Speaker Bureau; Shockwave Medical: Ownership Interests: Stocks, Stock Options; R. E. Davies: Medtronic: Speaker Bureau; Asahi Intec: Speaker Bureau; Shockwave: Advisory Board/Board Member; Siemens healthineers/Corindus: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; D. Doshi: speaker’s bureau for Abbott Vascular, Boston Scientific, and Medtronic and has research support from Biotronik: Consulting; M. B. Basir: consultant for Abbott Vascular, Abiomed, Cardiovascular Systems, Chiesi, and Zoll.: Consulting; E. S. Brilakis: Abbott: Consulting and Speaker Bureau; AMgen: Consulting and Speaker Bureau; Asahi Intecc: Speaker Bureau; Biotronik: Consulting and Speaker Bureau; Boston Scientific Corp.: Consulting, Principal Investigator for a Research Study and Speaker Bureau; ControlRad: Speaker Bureau; CSI: Consulting and Speaker Bureau; GE Healthcare: Consulting, Principal Investigator for a Research Study and Speaker Bureau; Hippocrates LLC: Ownership Interests: Stocks, Stock Options; MHI Ventures: Ownership Interests: Stocks, Stock Options; Cleerly Health: Ownership Interests: Stocks, Stock Options; Stallion Medical: Ownership Interests: Stocks, Stock Options; J. Karacsonyi Nothing to disclose. O. Krestyaninov Nothing to disclose. D. Khelimskii Nothing to disclose. P. Poomipanit Nothing to disclose. J. W. Choi Nothing to disclose. Ş. Görgülü Nothing to disclose. M. Koutouzis Nothing to disclose. I. Tsiafoutis Nothing to disclose. A. M. Sheikh Nothing to disclose. B. Elbarouni Nothing to disclose. T. Patel Nothing to disclose. R. W. Yeh Nothing to disclose. A. J. Kirtane Nothing to disclose. M. McEntegart Nothing to disclose. A. Masoumi Nothing to disclose. S. Kostantinis Nothing to disclose. B. Simsek Nothing to disclose. B. V. Rangan Nothing to disclose. O. C. Mastrodemos Nothing to disclose. Y. B. Sandoval Nothing to disclose. M. S. Megaly Nothing to disclose. I. Ungi Nothing to disclose. N. Abi Rafeh Nothing to disclose. Ö. Göktekin Nothing to disclose. K. Alaswad: consultant and speaker for Boston Scientific, Abbott Cardiovascular, Teleflex, and CSI: Consulting; J. Khatri: Medtronic, Abbott, Boston, Terumo, Asahi speaker/proctor.: Consulting; F. A. Jaffer: sponsored research support from Kowa, Canon, Siemens, Teleflex, Shockwave, and Amarin; consultant for Boston Scientific, Abbott Vascular, Siemens, Magenta Medical, Asahi Intecc and IMDS; has an equity interest in Intravascular Imaging, Inc. and DurVena, I: Consulting; M. P. Patel: Abbott: Consulting; Cardiovascular Systems, Inc.: Consulting; Medtronic: Consulting; A. Elguindy: Honoraria: Medtronic, Boston Scientific, Asahi Intecc, Abbott Proctorship fees: Medtronic, Boston Scientific, Asahi Intecc, Terumo Educational grants: Medtronic: Consulting; B. Jefferson: honoraria/consulting/speaking fees from Abbott, Boston Scientific, CSI, Medtronic: Consulting; J. R. Wollmuth: reports serving as proctor/speaker/medical advisory board for Abbott Vascular, Boston Scientific and Abiomed, proctor for Asahi Intecc, and medical advisory board with Philips: Advisory Board/Board Member; D. Karmpaliotis: Abbott: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; Saranas: Ownership Interests: Stocks, Stock Options; Soundbite: Ownership Interests: Stocks, Stock Options; Traverse Vascular: Ownership Interests: Stocks, Stock Options; Z. A. Ali: Abbott: Advisory Board/Board Member; Boston Scientific Corp.: Consulting and Speaker Bureau; Cardiovascular Systems, Inc.: Principal Investigator for a Research Study; Amgen: Advisory Board/Board Member; Astra Zeneca: Speaker Bureau; Shockwave Medical: Ownership Interests: Stocks, Stock Options; R. E. Davies: Medtronic: Speaker Bureau; Asahi Intec: Speaker Bureau; Shockwave: Advisory Board/Board Member; Siemens healthineers/Corindus: Speaker Bureau; Boston Scientific Corp.: Speaker Bureau; D. Doshi: speaker’s bureau for Abbott Vascular, Boston Scientific, and Medtronic and has research support from Biotronik: Consulting; M. B. Basir: consultant for Abbott Vascular, Abiomed, Cardiovascular Systems, Chiesi, and Zoll.: Consulting; E. S. Brilakis: Abbott: Consulting and Speaker Bureau; AMgen: Consulting and Speaker Bureau; Asahi Intecc: Speaker Bureau; Biotronik: Consulting and Speaker Bureau; Boston Scientific Corp.: Consulting, Principal Investigator for a Research Study and Speaker Bureau; ControlRad: Speaker Bureau; CSI: Consulting and Speaker Bureau; GE Healthcare: Consulting, Principal Investigator for a Research Study and Speaker Bureau; Hippocrates LLC: Ownership Interests: Stocks, Stock Options; MHI Ventures: Ownership Interests: Stocks, Stock Options; Cleerly Health: Ownership Interests: Stocks, Stock Options; Stallion Medical: Ownership Interests: Stocks, Stock Options; J. Karacsonyi Nothing to disclose. O. Krestyaninov Nothing to disclose. D. Khelimskii Nothing to disclose. P. Poomipanit Nothing to disclose. J. W. Choi Nothing to disclose. Ş. Görgülü Nothing to disclose. M. Koutouzis Nothing to disclose. I. Tsiafoutis Nothing to disclose. A. M. Sheikh Nothing to disclose. B. Elbarouni Nothing to disclose. T. Patel Nothing to disclose. R. W. Yeh Nothing to disclose. A. J. Kirtane Nothing to disclose. M. McEntegart Nothing to disclose. A. Masoumi Nothing to disclose. S. Kostantinis Nothing to disclose. B. Simsek Nothing to disclose. B. V. Rangan Nothing to disclose. O. C. Mastrodemos Nothing to disclose. Y. B. Sandoval Nothing to disclose. M. S. Megaly Nothing to disclose. I. Ungi Nothing to disclose. N. Abi Rafeh Nothing to disclose. Ö. Göktekin Nothing to disclose.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,359 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,001 | 0,001 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».